Integra LifeSciences (IART) Cuts FY26 Sales, EPS Outlook; Q3 Prelims Issued
Integra LifeSciences (IART) reported Q3 2026 preliminary revenue of $410M–$412M and EPS of $0.55–$0.59, reducing FY26 outlook to $1.634B–$1.654B revenue and $2.30–$2.40 EPS, attributing the cuts to July flooding. The company expects $190M–$200M operating cash flow for 2026.
How this was made
The 30-second read
Why it matters
The guidance cut is a primary market‑moving event, likely prompting sell‑side analysts to downgrade forecasts.
Market read
First report of FY26 guidance reduction; material for traders with exposure to med‑tech equities.
What to watch
Potential upside from faster production ramp post‑flood recovery.
Background
Integra LifeSciences disclosed unaudited Q3 2026 prelims and revised FY26 guidance after a July flooding event impacted operations.
Ticker impact
Integra LifeSciences cut FY26 revenue to $1.634B‑$1.654B and EPS to $2.30‑$2.40, issuing Q3 prelims of $410M‑$412M revenue and $0.55‑$0.59 EPS.
downward pressure as investors price in lower revenue and earnings outlook
The new FY26 guidance is materially below prior expectations and includes a specific operational risk (July flooding).
Market effects
Medical device sector may see broader scrutiny of flood‑risk exposure.
U.S. healthcare stocks could experience modest pullback.
Limited to investors tracking U.S. med‑tech earnings.
Counterpoint
If insurance recoveries exceed expectations, the downside could be overstated.
Key entities
- CompanyIntegra LifeSciences
Medical device and regenerative medicine firm.
